Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01298310CT.gov A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Morton Neuroma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Xylocaine (this asset) | AstraZeneca | Early P1 | CC · 43 |
| Cntx-4975 | Centrexion Therapeutics | P2 | B |
| Acetylcysteine | University of Arizona | P2 | CCC |
| Resiniferatoxin | National Institutes of Health Clinical Center (CC) | P1 | CC |
| Capsaicin | Centrexion Therapeutics | P1 | CC |
| Lidocaine | Oregon Health and Science University | P1 | CC |
Other indications for Xylocaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vertebral Column Disorder | — | P4 | BB · 68 |
| Stroke Disorder | — | P2 | CCC · 51 |
| Complex Regional Pain Syndrome | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Xylocaine in Morton Neuroma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/xylocaine-morton-neuroma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →